睿知中国疾病研究地图
候选清单0

乌鲁木齐新疆医科大学

新疆医科大学第一附属医院

First Affiliated Hospital of Xinjiang Medical University

在本站收录的 53 种疾病中,这家医院列在其中 13 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

新疆医科大学第一附属医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma29 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma22 篇牵头论文
  3. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  4. 骨肉瘤Osteosarcoma1 篇牵头论文
  5. 多发性骨髓瘤Multiple myeloma3 篇牵头论文
  6. 再生障碍性贫血Aplastic anaemia2 篇牵头论文
  7. 大动脉炎Takayasu arteritis0 篇牵头论文
  8. 肝包虫病Hepatic echinococcosis42 篇牵头论文
  9. 特发性肺纤维化Idiopathic pulmonary fibrosis0 篇牵头论文
  10. 白塞病Behçet disease1 篇牵头论文
  11. IgA 肾病IgA nephropathy0 篇牵头论文
  12. 成骨不全症Osteogenesis imperfecta0 篇牵头论文
  13. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文

未列出的收录疾病:鼻咽癌、胃癌、肝母细胞瘤、脊索瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 29 篇,占 1.0%。

牵头论文
29
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 6620222023: 5520232024: 6620242025: 882025

乌鲁木齐有 2 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题分子标志物与基因免疫治疗放疗
论文中的科室病理/检验科消化/肝病科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文29
  1. 5-FU Resistance Facilitates Immune Evasion in Esophageal Squamous Cell Carcinoma Through ADAM10-Mediated PD-L1 Shedding and Tumour Microenvironment Remodelling.2026Immunology
  2. Prognostic Value of UBE2S, HIF-1α, and FOXM1 Expression in Esophageal Squamous Cell Carcinoma.2025Analytical cellular pathology (Amsterdam)免费全文
  3. Lipidomic and transcriptomic analysis and its therapeutic implications in Chinese Kazakh patients with esophageal squamous cell carcinoma.2025BMC cancer免费全文
  4. PANoptosis-driven molecular stratification in esophageal squamous cell carcinoma: A multi-omics prognostic model and FGFR-Targeted therapeutic validation.2025Computers in biology and medicine
  5. PSD3 as a context-dependent modulator of immune landscape and tumor aggressiveness in esophageal squamous cell carcinoma.2025Frontiers in immunology免费全文
  6. WISP1 drives esophageal squamous cell carcinoma progression via modulation of cancer-associated fibroblasts and immune microenvironment.2025Frontiers in immunology免费全文
  7. ZNF468/AURKA/PI3K/AKT Positive Feedback Loop Promotes Proliferation and Metastasis of Oesophageal Squamous Cell Carcinoma.2025Journal of cellular and molecular medicine免费全文
  8. The ferroptotic effect of NRF2-GCLM signaling axis derived by radiotherapy of esophageal squamous cell cancer: the vivo study.2025Scientific reports免费全文
  9. PSD3, regulated by PKM2, endows growth and metastasis advantages in esophageal squamous cell carcinoma by modulating EMT progression.2025Scientific reports免费全文
  10. ZNF468 inhibits irradiation-induced G2/M cell cycle arrest and apoptosis by facilitating AURKA transcription in Esophageal Squamous Cell Carcinoma.2024Biochemical and biophysical research communications
  11. Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma.2024Biochimica et biophysica acta. Molecular cell research
  12. Nuclear factor erythroid 2-related factor 2 promotes radioresistance by regulating glutamate-cysteine ligase modifier subunit and its unique immunoinvasive pattern.2024Biomolecules & biomedicine免费全文
  13. Expression and Clinicopathological Significance of Extracellular Matrix Remodeling Markers in Esophageal Squamous Carcinoma.2024Critical reviews in eukaryotic gene expression
  14. Immune cell infiltration and drug sensitivity in PIK3CA-mutated esophageal squamous cell carcinoma: A TCGA database analysis.2024Human immunology
  15. NME4 suppresses NFκB2-CCL5 axis, restricting CD8+ T cell tumour infiltration in oesophageal squamous cell carcinoma.2024Immunology
  16. LEPRE1 shapes a non-flamed tumour immune landscape and predicts the prognosis in esophageal squamous cell carcinoma.2023Clinical and translational medicine免费全文
  17. Prognostic value of Nrf2/HO-1 expression and its correlation with occurrence in esophageal squamous cell carcinoma.2023Genes & genomics
  18. The expression of annexin-A1 in esophageal squamous cell carcinoma and its association with the biological behavior of the primary human esophageal squamous carcinoma cell line.2023Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  19. Construction of a prognostic model for radical esophagectomy based on immunohistochemical prognostic markers combined with clinicopathological factors.2023Medicine免费全文
  20. NRF2/HO-1 axis, BIRC5, and TP53 expression in ESCC and its correlation with clinical pathological characteristics and prognosis.2023The International journal of biological markers
  21. Prognostic Value of GPNMB, EGFR, p-PI3K, and Ki-67 in Patients with Esophageal Squamous Cell Carcinoma.2022Analytical cellular pathology (Amsterdam)免费全文
  22. The Relationship between MACC1/c-Met/Cyclin D1 Axis Expression and Prognosis in ESCC.2022Analytical cellular pathology (Amsterdam)免费全文
  23. Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma.2022Journal of immunology research免费全文
  24. Establishment of esophageal squamous carcinoma cell lines with different invasive metastatic potential and differential gene screening.2022Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  25. Proteomic profiling of plasma exosomes reveals CD82 involvement in the development of esophageal squamous cell carcinoma.2022Journal of proteomics
  26. Tumor-infiltrating lymphocyte signature in epithelial and stromal compartments of an esophageal squamous cell carcinoma acidic microenvironment mediated by MCT4.2022Pathology, research and practice
  27. CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway.2021Journal of cellular physiology
  28. Clinical significance of YAP1 and TAZ in esophageal squamous cell carcinoma.2021Medicine免费全文
  29. Plasma‑derived exosomal pyruvate kinase isoenzyme type M2 accelerates the proliferation and motility of oesophageal squamous cell carcinoma cells.2021Oncology reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
PubMed 以外找到的论文(未计入)8
  1. Additional file 1 of Lipidomic and transcriptomic analysis and its therapeutic implications in Chinese Kazakh patients with esophageal squamous cell carcinoma2025Figshare论文
  2. Lipidomic and transcriptomic analysis and its therapeutic implications in Chinese Kazakh patients with esophageal squamous cell carcinoma2025Figshare补充材料
  3. Vasculogenic mimicry and p53 expression in esophageal squamous cell carcinoma patients of Kazakh ethnicity, the association between vasculogenic mimicry and p53 expression and its influence on prognosis2025International Surgery Journal论文
  4. Overexpression of CXCL5 promotes proliferation and infiltration of esophageal squamous cell carcinoma2023Research Square预印本
  5. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncology会议摘要
  6. Correlation Of SOX17, MACC1, c-Met With Clinicopathological Features And Prognosis of Esophageal Squamous Cell Carcinoma2021Research Square预印本
  7. Retrospective Analyses of the Clinicopathological and Prognostic Features of Esophageal Squamous Cell Carcinoma in a Grade A Tertiary Hospital in Xinjiang, China2021未列出期刊预印本
  8. The effect of SOX17, MACC1 and c-Met expression in ESCC on prognosis2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 22 篇,占 0.1%。

牵头论文
22
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 101020222023: 1120232024: 1120242025: 552025

乌鲁木齐有 1 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题局部治疗(消融、TACE、HAIC)复发与预后影像、人工智能与早期发现
论文中的科室影像/核医学科普外/肝胆胰外科病理/检验科消化/肝病科
牵头的论文22
  1. Artificial intelligence-driven CT radiomics model predicts prognosis in TACE-refractory hepatocellular carcinoma.2026Abdominal radiology (New York)免费全文
  2. Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends.2025Human vaccines & immunotherapeutics免费全文
  3. Synergistic and toxicity‑reducing effects of acteoside as an adjuvant therapy of oxaliplatin against hepatocellular carcinoma.2025International journal of oncology免费全文
  4. An integrated chemokine-based machine learning model predicts prognosis and guides immunotherapy in hepatocellular carcinoma.2025Medicine免费全文
  5. Hepatitis B-associated cirrhosis combined with multiple nodular fatty infiltrates of the liver: A rare benign disease misdiagnosed as hepatocellular carcinoma - a case report.2025Medicine免费全文
  6. METTL14 suppresses the migration and invasion of hepatocellular carcinoma cells by m6A methylation of RPLP2.2025Scientific reports免费全文
  7. The novel predictive nomograms for early death in metastatic hepatocellular carcinoma: A large cohort study.2024Medicine免费全文
  8. Rapid detection of serological biomarkers in gallbladder carcinoma using fourier transform infrared spectroscopy combined with machine learning.2023Talanta
  9. Natural history of decompensated cirrhosis with serum hepatitis B DNA < 2000 IU/mL: a retrospective study.2022BMC gastroenterology免费全文
  10. Surgical resection versus radiofrequency ablation for early recurrent hepatocellular carcinoma.2022European journal of gastroenterology & hepatology
  11. Roles of immune cells in the concurrence of Echinococcus granulosus sensu lato infection and hepatocellular carcinoma.2022Experimental parasitology
  12. LncRNA NEAT1 sponges miR-214 to promoted tumor growth in hepatocellular carcinoma.2022Mammalian genome : official journal of the International Mammalian Genome Society
  13. Curative Analysis of Patients with Hepatocellular Carcinoma Using Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation.2022Medical science monitor : international medical journal of experimental and clinical research免费全文
  14. Repeat hepatic resection VS radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma: an updated meta-analysis.2022Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  15. Upregulated TUBG1 expression is correlated with poor prognosis in hepatocellular carcinoma.2022PeerJ免费全文
  16. Urine fluorescence spectroscopy combined with machine learning for screening of hepatocellular carcinoma and liver cirrhosis.2022Photodiagnosis and photodynamic therapy
  17. Urine surface-enhanced Raman spectroscopy combined with SVM algorithm for rapid diagnosis of liver cirrhosis and hepatocellular carcinoma.2022Photodiagnosis and photodynamic therapy
  18. Hsa_circ_0008092 Contributes to Cell Proliferation and Metastasis in Hepatocellular Carcinoma via the miR-502-5p/CCND1 Axis.2022Protein and peptide letters
  19. Vascular normalization therapy with targeted localized vessel bevacizumab infusion in hepatocellular carcinoma after transarterial chemoembolization failure.2021Annals of palliative medicine
  20. MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway.2021Bioscience reports免费全文
  21. Connexin32 activates necroptosis through Src-mediated inhibition of caspase 8 in hepatocellular carcinoma.2021Cancer science免费全文
  22. Mesenchymal stem cell-derived exosomes block malignant behaviors of hepatocellular carcinoma stem cells through a lncRNA C5orf66-AS1/microRNA-127-3p/DUSP1/ERK axis.2021Human cell
中文论文(未计入)1
  1. [Analysis of PIKFYVE gene expression, clinical significance, and experimental validation based on TCGA database in hepatocellular carcinoma].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  2. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  3. Prospective Surveillance for Very Early Hepatocellular Carcinoma状态不明NCT03588442研究中心2018-07 启动
  4. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC状态不明NCT03313596研究中心III期2013-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

乌鲁木齐有 1 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.04%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

乌鲁木齐有 12 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.2%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

乌鲁木齐有 1 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录
研究主题联合用药诊断、微小残留病与危险分层

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

乌鲁木齐有 1 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题干细胞移植感染与支持治疗
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

乌鲁木齐有 1 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis即将招募NCT07451665研究中心IV期2026-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 42 篇,占 27.6%。

牵头论文
42
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 4420222023: 3320232024: 131320242025: 992025

乌鲁木齐有 5 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科影像/核医学科消化/肝病科儿科
牵头的论文42
  1. Ex vivo liver resection and autotransplantation for hepatic alveolar echinococcosis with cavernous transformation of the portal vein.2026Hepatobiliary & pancreatic diseases international : HBPD INT
  2. Transplantation as a treatment option for hepatic echinococcosis past, present, and future - a pooled data analysis of 476 patients.2026International journal of surgery (London, England)
  3. Exploring the mechanism and drug candidates of alveolar echinococcosis affecting liver fibrosis through analysis of existing microarray data.2025Acta tropica
  4. CT-based radiomics models using intralesional and different perilesional signatures in predicting the microvascular density of hepatic alveolar echinococcosis.2025BMC medical imaging
  5. Serum Metabolomics of Patients with Hepatic Cystic Echinococcosis.2025Biomedical chromatography : BMC
  6. Inhibition of the MyD88/NF-κB pathway alters the Th1/Th2 balance to exacerbate liver injury and hepatic fibrosis in alveolar echinococcosis.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  7. IL-22-STAT3-CD155 axis in alveolar echinococcosis: a pivotal role in immune exhaustion and therapeutic potential.2025Frontiers in immunology
  8. Hepatic alveolar echinococcosis infection induces a decrease in NK cell function through high expression of NKG2A in patients.2025Frontiers in immunology
  9. Laparoscopic procedure versus conventional cystectomy for pediatric hepatic cystic echinococcosis:a controlled clinical study.2025Langenbeck's archives of surgery
  10. Prevalence and determinants of frailty-sarcopenia comorbidity in hospitalized patients undergoing liver transplantation for hepatic echinococcosis.2025Transplant immunology
  11. Identification of key factors and explainability analysis for surgical decision-making in hepatic alveolar echinococcosis assisted by machine learning.2025World journal of gastroenterology
  12. sCD155 as a potential marker for diagnosing the vascular invasion in hepatic alveolar echinococcosis.2024Acta tropica
  13. Successful Interventional Therapy for Portal Vein Stenosis after Ex Vivo Liver Resection and Autotransplantation in End-Stage Hepatic Alveolar Echinococcosis with Cavernous Transformation.2024Annals of transplantation
  14. Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo Liver Resection and Autotransplantation.2024Annals of transplantation
  15. Liver autotransplantation and atrial reconstruction on a patient with multiorgan alveolar echinococcosis: a case report.2024BMC infectious diseases
  16. Ultrasonography screening of hepatic cystic echinococcosis in sheep flocks used for evaluating control progress in a remote mountain area of Hejing County, Xinjiang.2024BMC veterinary research
  17. Applying LASSO logistic regression for the prediction of biliary complications after ex vivo liver resection and autotransplantation in patients with end-stage hepatic alveolar echinococcosis.2024European journal of medical research
  18. Portal vein embolization combined with ex vivo liver resection and autotransplantation: A novel treatment strategy for end-stage and metastatic hepatic alveolar echinococcosis.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  19. Drug repurposing for hard-to-treat human alveolar echinococcosis: pyronaridine and beyond.2024Parasitology
  20. Induced hepatocyte-like cells derived from adipose-derived stem cells alleviates liver injury in mice infected with Echinococcus Multilocularis.2024Scientific reports
  21. Efficiency of Anatomical Hepatectomy in the Treatment of Hepatic Cystic Echinococcosis.2024Surgical infections
  22. Clinical Application of Artificial Intelligence in the Ultrasound Classification of Hepatic Cystic Echinococcosis.2024The American journal of tropical medicine and hygiene
  23. Multiclassification of Hepatic Cystic Echinococcosis by Using Multiple Kernel Learning Framework and Ultrasound Images.2024Ultrasound in medicine & biology
  24. Fifty-five cases of hepatic alveolar echinococcosis combined with lymph node metastasis: A retrospective study.2024World journal of gastroenterology
  25. Multidetector computed tomography assessment of venous invasion in hepatic alveolar echinococcosis.2023Abdominal radiology (New York)
  26. Collateral circulation caused by end-stage hepatic alveolar echinococcosis.2023BMC infectious diseases
  27. Oral Delivery of Anti-Parasitic Agent-Loaded PLGA Nanoparticles: Enhanced Liver Targeting and Improved Therapeutic Effect on Hepatic Alveolar Echinococcosis.2023International journal of nanomedicine
  28. Massive sympathetic nerve infiltration in advanced hepatic alveolar echinococcosis: a case report and review of the literature.2022BMC infectious diseases
  29. Application of hepatic lobe hyperplasia techniques in the treatment of advanced hepatic alveolar echinococcosis: a single-centre experience.2022BMC surgery
  30. Automatic Classification of Hepatic Cystic Echinococcosis Using Ultrasound Images and Deep Learning.2022Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  31. Approaches to reconstruction of inferior vena cava by ex vivo liver resection and autotransplantation in 114 patients with hepatic alveolar echinococcosis.2022World journal of gastroenterology
  32. Identification of infiltrating immune cell subsets and heterogeneous macrophages in the lesion microenvironment of hepatic cystic echinococcosis patients with different cyst viability.2021Acta tropica
  33. Quantitative evaluation of range and metabolic activity of hepatic alveolar echinococcosis lesion microenvironment using PET/CT and multi-site sampling method.2021BMC infectious diseases
  34. Double versus single T-tube drainage for frank cysto-biliary communication in patients with hepatic cystic echinococcosis: a retrospective cohort study with median 11 years follow-up.2021BMC surgery
  35. Impact of Albendazole on Cytokine and Chemokine Response Profiles in Echinococcus multilocularis-Inoculated Mice.2021BioMed research international
  36. Hepatic Alveolar Echinococcosis: Predictive Biological Activity Based on Radiomics of MRI.2021BioMed research international
  37. Single-Cell RNA Sequencing Reveals the Heterogeneity of Infiltrating Immune Cell Profiles in the Hepatic Cystic Echinococcosis Microenvironment.2021Infection and immunity
  38. Laparoscopic or open treatment for hepatic alveolar echinococcosis: A single-institution experience.2021International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  39. An improved experimental method for simultaneously isolating hepatocytes and hepatic stellate cells in mouse liver infected with Echinococcus multilocularis.2021Journal of clinical laboratory analysis
  40. Laparoscopic hepatectomy for the treatment of hepatic alveolar echinococcosis.2021Parasite (Paris, France)
  41. Use of the ligamentum teres hepatis for outflow reconstruction during ex vivo liver resection and autotransplantation in patients with hepatic alveolar echinococcosis: A case series of 24 patients.2021Surgery
  42. Feasibility of Retrohepatic Inferior Vena Cava Resection Without Reconstruction for Hepatic Alveolar Echinococcosis.2021The American surgeon
中文论文(未计入)1
  1. [Simultaneous combined radical surgery for hepatic and renal alveolar echinococcosis: an analysis of 10 clinical cases].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
早期论文(2016–2020 年)27
  1. Kupffer Cells: Important Participant of Hepatic Alveolar Echinococcosis.2020Frontiers in cellular and infection microbiology
  2. Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.2020Hepatology (Baltimore, Md.)
  3. Left trisectionectomy and supra-hepatic caval reconstruction with vascular prosthesis for chronic Budd-Chiari syndrome caused by hepatic alveolar echinococcosis.2019Chinese medical journal
  4. Resection of retrohepatic inferior vena cava without reconstruction for hepatic alveolar echinococcosis.2019Chinese medical journal
  5. Compared efficacy of University of Wisconsin and histidine-tryptophan-ketoglutarate solutions in ex-situ liver resection and autotransplantation for end-stage hepatic alveolar echinococcosis patients.2019Hepatobiliary & pancreatic diseases international : HBPD INT
  6. Simultaneous occurrence of hepatic alveolar and cystic echinococcosis.2019Journal of helminthology
  7. Differentiation between hepatic cystic echinococcosis types 1 and simple hepatic cysts: A retrospective analysis.2019Medicine
  8. Subcutaneous Inoculation of Echinococcus multilocularis Induces Delayed Regeneration after Partial Hepatectomy.2019Scientific reports
  9. Ex vivo liver resection and autotransplantation as alternative to allotransplantation for end-stage hepatic alveolar echinococcosis.2018Journal of hepatology
  10. Quantitative characterization and diagnosis via hard X-ray phase-contrast microtomography.2018Microscopy research and technique
  11. Plasma IL-23 and IL-5 as surrogate markers of lesion metabolic activity in patients with hepatic alveolar echinococcosis.2018Scientific reports
  12. Comparison of [18F]Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced Ultrasound for Evaluation of Hepatic Alveolar Echinococcosis Activity.2018Ultrasound in medicine & biology
  13. Comparison of Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance (MR) Imaging to T1 Mapping in Characterization of Hepatic Alveolar Echinococcosis.2017Medical science monitor : international medical journal of experimental and clinical research
  14. Recurrent multiple-organ involvement of disseminated alveolar echinococcosis in 3 patients: Case report.2017Medicine
  15. Cloning and characterization of an Echinococcus granulosus ecdysteroid hormone nuclear receptor HR3-like gene.2017Parasite (Paris, France)
  16. T-cell tolerance and exhaustion in the clearance of Echinococcus multilocularis: role of inoculum size in a quantitative hepatic experimental model.2017Scientific reports
  17. Novel Interventional Management of Hepatic Hydatid Cyst with Nanosecond Pulses on Experimental Mouse Model.2017Scientific reports
  18. Molecular Cloning and Characterization of Ribosomal Protein RPS9 in Echinococcus granulosus.2017The Journal of parasitology
  19. Improved experimental model of hepatic cystic hydatid disease resembling natural infection route with stable growing dynamics and immune reaction.2017World journal of gastroenterology
  20. Ex Vivo Liver Resection and Autotransplantation for End-Stage Alveolar Echinococcosis: A Case Series.2016American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  21. Surgical Procedure Choice for Removing Hepatic Cysts of Echinococcus granulosus in Children.2016European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie
  22. Surgical treatment of hepatic cystic echinococcosis in patients co-infected with HIV/AIDS.2016Journal of helminthology
  23. Comparative Evaluation of Liposomal Albendazole and Tablet-Albendazole Against Hepatic Cystic Echinococcosis: A Non-Randomized Clinical Trial.2016Medicine
  24. Assessment of Vascularity in Hepatic Alveolar Echinococcosis: Comparison of Quantified Dual-Energy CT with Histopathologic Parameters.2016PloS one
  25. Immunological Characteristics of Recurrent Echinococcosis-Induced Anaphylactic Shock.2016The American journal of tropical medicine and hygiene
  26. [Application of three-dimensional visualization technology in surgical treatment for patients with hepatic alveolar echinococcosis].2016Zhonghua wai ke za zhi [Chinese journal of surgery]
  27. [Living donor liver transplantation for the treatment complicated hepatic cystic echinococcosis: first case report from China].2016Zhonghua yi xue za zhi

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年没有牵头特发性肺纤维化的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

乌鲁木齐有 3 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Research Progress in the Pathogenesis of Idiopathic Pulmonary Fibrosis with Lung Cancer].2020Zhongguo fei ai za zhi = Chinese journal of lung cancer
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

乌鲁木齐有 1 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

乌鲁木齐有 2 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  2. Atrasentan in Patients With IgA Nephropathy进行中,不再招募NCT04573478研究中心III期2020-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

乌鲁木齐有 1 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Genotypes and phenotypes of nine Uygur children with osteogenesis imperfecta in Xinjiang].2020Zhonghua er ke za zhi = Chinese journal of pediatrics

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

乌鲁木齐有 1 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Increased expression of IL-9 in peripheral blood and liver tissues of patients with primary biliary cirrhosis].2016Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis正在招募NCT06051617研究中心III期2023-09 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

新疆医科大学第一附属医院

First Affiliated Hospital of Xinjiang Medical University

乌鲁木齐

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
First Affiliated Hospital of XinJiang Medical University; First Affiliated Hospital of Xinjiang Medical University (XJMU); he First Affiliated Hospital of Xinjiang Medical University

提出更正下载数据